What is wrong in doing good?
ferric carboxymaltose
hypophosphataemia
iron deficiency anemia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
24
07
2023
accepted:
25
07
2023
medline:
12
9
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Hypophosphataemia is a common side-effect in patients with iron deficiency anaemia treated with ferric carboxymaltose, which is not a class effect of all intravenous (IV) iron formulations. The report by Chu et al. shows that moderate and severe hypophosphataemia is common and can even require IV supplementation of phosphate with unknown long-term consequences. Commentary on: Chu et al. Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-a 3-year experience from a single institution in Singapore. Br J Haematol 2023;202:1199-1204.
Substances chimiques
ferric carboxymaltose
6897GXD6OE
Ferric Compounds
0
Iron
E1UOL152H7
Maltose
69-79-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1089-1090Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Chu Z, Cushway T, Wong M, Lim KX, Peh WM, Ng CT, et al. Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-a 3-year experience from a single institution in Singapore. Br J Haematol. 2023;202:1199-1204.
Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-853.e1-2. https://doi.org/10.1053/j.gastro.2011.06.005
Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83-S92. https://doi.org/10.1111/hdi.12560
Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020;75:100862. https://doi.org/10.1016/j.mam.2020.100862
Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022;154:116202. https://doi.org/10.1016/j.bone.2021.116202
Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72:644-653. https://doi.org/10.1136/gutjnl-2022-327897
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323:432-443. https://doi.org/10.1001/jama.2019.22450
Schaefer B, Zoller H, Wolf M. Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. J Clin Endocrinol Metab. 2022;107:1009-1019. https://doi.org/10.1210/clinem/dgab852
Frazier R, Hodakowski A, Cai X, Lee J, Zakarija A, Stein B, et al. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: a single-center prospective observational study of women with iron deficiency. Bone. 2020;141:115559. https://doi.org/10.1016/j.bone.2020.115559
Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3. https://doi.org/10.1172/jci.insight.124486